Projecting future drug expenditures - 1997

American Journal of Health-System Pharmacy

Volumn 54, Issue 2, 1997, Pages 153-161

  Mehl, Bernard ^a   Santell, John P ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

Author keywords

Administration; Budgets; Costs; Economics; Health maintenance organizations; Industry, pharmaceuticals; Integrated health care; Legislation; Pharmaco economics; Pharmacy, institutional; Purchasing

Indexed keywords

BIOTECHNOLOGY; BUDGET; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; PHARMACY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PURCHASING; REVIEW; UNITED STATES;

EID: 0031020253     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.2.153     Document Type: Review

References (24)

1. Tokarski C. The case of the vanishing patient. In: Service R, ed. The state of health care in America, 1996. Montvale, NJ: Hoechst-Marion Roussel; 1996:36-8.
2. Robinson M. Health care becomes big business. In: Service R, ed. The state of health care in America, 1996. Montvale, NJ: Hoechst-Marion Roussel; 1996:29-32.
3. Santell JP. Projecting future drug expenditures - 1996. Am J Health-Syst Pharm. 1996; 53:139-50.
4. Santell JP. Projecting future drug expenditures - 1995. Am J Health-Syst Pharm. 1995; 52:151-63.
5. Santell JP. Projecting future drug expenditures - 1994. Am J Hosp Pharm. 1994; 51:177-87.
6. Santell JP. Projecting future drug expenditures - 1993. Am J Hosp Pharm. 1993; 50:71-7.
7. Health Care Purchasing News. 1996; 20:(7).
8. Mehl B. 1993 changes in drug costs for inpatient services. Hosp Pharm. 1994; 29:771-3.
9. Ciba Geneva pharmacy benefit report. Trends and forecasts. Summit, NJ: Ciba Geneva Pharmaceuticals; 1996.
10. Horn SD, Sharkey PD, Tracy DM et al. Intended and unintended consequences of HMO cost-containment strategies: results from the Managed Care Outcomes Project. Am J Manag Care. 1996; 2:253-64.
11. Horn SD. Unintended consequences of drug formularies. Am J Health-Syst Pharm. 1996; 53:2204-6.
12. Sanchez LA. Evaluating the quality of published pharmacoeconomic evaluations. Hasp Pharm. 1994; 30:146-8.
13. Lee JT, Sanchez LA. Interpretation of "cost-effectiveness" and soundness of economic evaluations in the pharmacy literature. Am J Hasp Pharm. 1991; 48:2622-7.
14. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 334:677-81.
15. Rhône-Poulenc's Taxotere and Schering's Fareston could clear PDA in early 1996, continuing roll of oncology drugs. FDC Rep. 1996; 58(Jan 8):8-9.
16. Hussar DA. New therapeutic agents marketed in the first half of 1996. Pharm Today. 1996; 2(7):11.
17. New drug approvals update. Rockville, MD: U.S. Food and Drug Administration Center for Drug Evaluation and Research; 1996 Jul 8.
18. Athena Neuroscience's Zanaflex and J&J's Topamax likely to seize approvals by end of 1996. FDC Rep. 1996; 58(Aug 12):33.
19. Burstin HR, Lipsitz SR, Udvarhelyi S et al. The effect of hospital financial characteristics on quality of care. JAMA. 1993; 270:845-9.
20. Kravitz RL, Romano PS. Managed care cost containment and the law of unintended consequences. Am J Manag Care. 1996; 2:323-4.
21. Feder BJ. Drug makers' settlement blocked. N Y Times. 1996; Apr 5:D-1.
22. McDowell E. Judge agrees to settlement in drug case. N Y Times. 1996; Jun 21:A-31.
23. Drug pricing investigation. New York: Gruntal Investment Research; 1996 May 16:1.
24. Langreth R. Settlement cleared in pharmacists' suit over price fixing, but debate lingers. Wall St J. 1996; Jun 24:B5.